Phase 3 Recruiting NIH
This phase III trial compares the effect of adding cetuximab to pembrolizumab versus pembrolizumab alone in treating patients with head and neck squamous cell carcinoma (HNSCC) that has come back after a period of improvement (recurrent) a…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06589804
Sites in New Jersey: - Memorial Sloan Kettering Basking Ridge — Basking Ridge, New Jersey
- Jefferson Cherry Hill Hospital — Cherry Hill, New Jersey
- Memorial Sloan Kettering Monmouth — Middletown, New Jersey
- Memorial Sloan Kettering Bergen — Montvale, New Jersey
- Sidney Kimmel Cancer Center Washington Township — Sewell, New Jersey
Phase 2, Phase 3 Recruiting Academic/Other
This phase II/III trial studies how well sentinel lymph node biopsy works and compares sentinel lymph node biopsy surgery to standard neck dissection as part of the treatment for early-stage oral cavity cancer. Sentinel lymph node biopsy s…
Sponsor: NRG Oncology
NCT ID: NCT04333537
Sites in New Jersey: - Memorial Sloan Kettering Basking Ridge — Basking Ridge, New Jersey
- Saint Barnabas Medical Center — Livingston, New Jersey
- Memorial Sloan Kettering Monmouth — Middletown, New Jersey
- Memorial Sloan Kettering Bergen — Montvale, New Jersey
- Rutgers Cancer Institute of New Jersey — New Brunswick, New Jersey
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the efficacy and safety of sonesitatug vedotin in combination with capecitabine with or without rilvegostomig in first-line (1L) Claudin18.2 (CLDN18.2)-positive, human epidermal growth factor recept…
Sponsor: AstraZeneca
NCT ID: NCT07431281
Sites in New Jersey: - Research Site — Camden, New Jersey
- Research Site — East Brunswick, New Jersey
- Research Site — Hackensack, New Jersey
- Research Site — New Brunswick, New Jersey
- Research Site — Summit, New Jersey
Phase 2, Phase 3 Recruiting Industry
Ficerafusp alfa is directed against two targets, Epidermal Growth Factor Receptor (EGFR) and Transforming Growth Factor beta (TGF-β). This study intends to evaluate the safety and efficacy of ficerafusp alfa in combination with pembrolizum…
Sponsor: Bicara Therapeutics
NCT ID: NCT06788990
Sites in New Jersey: - Site #0145 — Newark, New Jersey
Phase 3 Recruiting Industry
The purpose of this study is to compare anti-tumor activity of amivantamab in addition to pembrolizumab and carboplatin versus pembrolizumab, 5-fluorouracil (FU), and platinum therapy (carboplatin or cisplatin) in participants with refract…
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT07276399
Sites in New Jersey: - Rutgers Cancer Institute of New Jersey — New Brunswick, New Jersey
Phase 3 Recruiting Industry
This is a Phase 3 randomized, open-label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma.
Sponsor: Merus B.V.
NCT ID: NCT06525220
Sites in New Jersey: - Site 94 — Hackensack, New Jersey
Phase 2 Recruiting Network
This phase II trial studies how well radiation therapy with or without cisplatin works in treating patients with stage III-IVA squamous cell carcinoma of the head and neck who have undergone surgery. Radiation therapy uses high energy x-ra…
Sponsor: ECOG-ACRIN Cancer Research Group
NCT ID: NCT02734537
Sites in New Jersey: - Jersey City Medical Center — Jersey City, New Jersey
- Cooperman Barnabas Medical Center — Livingston, New Jersey
- Monmouth Medical Center — Long Branch, New Jersey
- Morristown Medical Center — Morristown, New Jersey
- Rutgers Cancer Institute of New Jersey — New Brunswick, New Jersey
Phase 2 Recruiting NIH
This phase II trial studies the effect of pembrolizumab alone compared to the usual approach (chemotherapy \[cisplatin and carboplatin\] plus radiation therapy) after surgery in treating patients with head and neck squamous cell carcinoma …
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04671667
Sites in New Jersey: - Memorial Sloan Kettering Basking Ridge — Basking Ridge, New Jersey
- Memorial Sloan Kettering Monmouth — Middletown, New Jersey
- Memorial Sloan Kettering Bergen — Montvale, New Jersey
Phase 1, Phase 2 Recruiting Industry
Phase 1 dose escalation will determine the first cycle dose-limiting toxicities (DLTs), the maximum tolerated dose (MTD), the biologically effective dose and recommended Phase 2 dose (RP2D) of repotrectinib given to adult subjects with adv…
Sponsor: Turning Point Therapeutics, Inc.
NCT ID: NCT03093116
Sites in New Jersey: - Local Institution - 2122 — New Brunswick, New Jersey
Phase 1, Phase 2 Recruiting Industry
The purpose of this study is to determine safety and preliminary efficacy of amivantamab monotherapy, amivantamab in addition to pembrolizumab, amivantamab in addition to paclitaxel and amivantamab in addition to pembrolizumab and carbopla…
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT06385080
Sites in New Jersey: - Rutgers Cancer Institute of New Jersey — New Brunswick, New Jersey
Phase 1, Phase 2 Recruiting Industry
This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1310 in subjects with advanced solid tumors.
Sponsor: DualityBio Inc.
NCT ID: NCT05785741
Sites in New Jersey: - Research site 119 — Florham Park, New Jersey
Phase 1, Phase 2 Recruiting Industry
This is a multicenter, open-label, Phase 1/2 study of orally administered VMD-928 monotherapy and in combination with pembrolizumab in adult subjects with advanced solid tumors or lymphoma that have progressed or are non responsive to avai…
Sponsor: VM Oncology, LLC
NCT ID: NCT03556228
Sites in New Jersey: - Englewood Hospital and Medical Center (site 202) — Englewood, New Jersey
- Summit Medical Group (site 205) — Florham Park, New Jersey
- Atlantic Health System, Morristown Medical Center (site 124) — Morristown, New Jersey
Phase 1, Phase 2 Recruiting Industry
The purpose of this study is to assess the safety, tolerability, and recommended dose(s) of BMS-986340 as monotherapy and in combination with nivolumab, docetaxel, or Pumitamig in participants with advanced solid tumors. This study is a fi…
Sponsor: Bristol-Myers Squibb
NCT ID: NCT04895709
Sites in New Jersey: - John Theurer Cancer Center — Hackensack, New Jersey
Phase 1, Phase 2 Recruiting Industry
This is a first in human, open-label, multi-center Phase 1 / 2 study to evaluate the safety, tolerability, and initial efficacy of AU-007, also known as imneskibart, in patients with advanced solid tumors. AU-007 will be administered eithe…
Sponsor: Aulos Bioscience, Inc.
NCT ID: NCT05267626
Sites in New Jersey: - Atlantic Healthcare System — Morristown, New Jersey
Phase 2 Recruiting Academic/Other
The purpose of this study to find out whether adding trastuzumab and pembrolizumab to standard chemotherapy is an effective treatment for resectable HER2+ esophagogastric cancer.
Sponsor: Memorial Sloan Kettering Cancer Center
NCT ID: NCT06123338
Sites in New Jersey: - Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) — Basking Ridge, New Jersey
- Memorial Sloan Kettering Monmouth (Limited Protocol Activities) — Middletown, New Jersey
- Memorial Sloan Kettering Bergen (Limited Protocol Activities) — Montvale, New Jersey
Phase 2 Recruiting Academic/Other
This study will look at whether monitoring HPV ctDNA levels is an effective way to detect cancer relapse risk in people with HPV-OPC. All participants will have recently had surgery to treat their disease, or they will be scheduled to have…
Sponsor: Memorial Sloan Kettering Cancer Center
NCT ID: NCT05307939
Sites in New Jersey: - Memorial Sloan Kettering Basking Ridge (Limited protocol activities) — Basking Ridge, New Jersey
- Memorial Sloan Kettering Monmouth (Limited Protocol Activities) — Middletown, New Jersey
- Memorial Sloan Kettering Bergen (Limited Protocol Activities) — Montvale, New Jersey
Phase 2 Recruiting Academic/Other
This study will test whether limiting standard photon intensity modulated radiation therapy (IMRT) to exclude the oral tongue surgical site can decrease the risk of side effects caused by oral radiation. The researchers will also find out …
Sponsor: Memorial Sloan Kettering Cancer Center
NCT ID: NCT06485778
Sites in New Jersey: - Memorial Sloan Kettering Basking Ridge — Basking Ridge, New Jersey
- Memorial Sloan Kettering Monmouth — Middletown, New Jersey
- Memorial Sloan Kettering Bergen — Montvale, New Jersey
Phase 2 Recruiting Academic/Other
The purpose of this study to find out whether sacituzumab govitecan in combination with cetuximab is an effective and safe treatment approach for people with recurrent and/or metastatic head and neck squamous cell cancer (HNSCC).
Sponsor: Memorial Sloan Kettering Cancer Center
NCT ID: NCT07063212
Sites in New Jersey: - Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities) — Basking Ridge, New Jersey
- Memorial Sloan Kettering Monmouth (Limited Protocol Activities) — Middletown, New Jersey
- Memorial Sloan Kettering Bergen (Limited Protocol Activities) — Montvale, New Jersey
Phase 2 Recruiting Academic/Other
The researchers are doing this study to find out if the combination of avutometinib and defactinib is an effective treatment for RAF dimer-driven radioiodine-refractory differentiated thyroid cancer or anaplastic thyroid cancer. The resear…
Sponsor: Memorial Sloan Kettering Cancer Center
NCT ID: NCT06007924
Sites in New Jersey: - Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) — Basking Ridge, New Jersey
- Memorial Sloan Kettering Monmouth (Limited Protocol Activities) — Middletown, New Jersey
- Memorial Sloan Kettering Bergen (Limited Protocol Activities) — Montvale, New Jersey
Phase 2 Recruiting Academic/Other
This clinical trial studies the effect of customized 3 dimensional (3D) printed oral tents on patients with head and neck cancer who are receiving radiotherapy. Oral stents are made from the impression of patients' mouth and cover patients…
Sponsor: M.D. Anderson Cancer Center
NCT ID: NCT04870762
Sites in New Jersey: - Cooper Hospital University Medical Center — Camden, New Jersey
Phase 2 Recruiting Academic/Other
The purpose of this study is to test the treatment approach of de-escalated radiation and chemotherapy followed by a planned neck dissection surgery in people with head and neck cancer. The study will look at how effective the treatment ap…
Sponsor: Memorial Sloan Kettering Cancer Center
NCT ID: NCT05544136
Sites in New Jersey: - Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities) — Basking Ridge, New Jersey
- Memorial Sloan Kettering Monmouth (Limited Protocol Activities) — Middletown, New Jersey
- Memorial Sloan Kettering Bergen (Limited Protocol Activities) — Montvale, New Jersey
Phase 2 Recruiting Academic/Other
This is a phase II clinical trial to assess the clinical activity of immunotherapy with E7 TCR-T cells for metastatic HPV-associated cancers. HPV-associated cancers in include cervical, throat, penile, vulvar, vaginal, anal, and other canc…
Sponsor: Christian Hinrichs
NCT ID: NCT05686226
Sites in New Jersey: - Rutgers Cancer Institute — New Brunswick, New Jersey
- RWJBarnabas Health - Robert Wood Johnson University Hospital — New Brunswick, New Jersey
Phase 1, Phase 2 Recruiting Academic/Other
The goal of this study is to determine the feasibility of administration of a single dose of E7 TCR-T cells as induction therapy prior to definitive treatment (chemoradiation or surgery) of locoregionally advanced HPV-associated cancers. T…
Sponsor: Christian Hinrichs
NCT ID: NCT05639972
Sites in New Jersey: - Rutgers Cancer Institute — New Brunswick, New Jersey
- RWJBarnabas Health - Robert Wood Johnson University Hospital — New Brunswick, New Jersey
Phase 2 Recruiting Academic/Other
The purpose of this study is to determine whether treatment of HPV-related oropharyngeal squamous cell carcinoma in patients with undetectable postoperative HPV circulating tumor DNA (cfHPVDNA) with transoral robotic surgery (TORS) alone c…
Sponsor: Icahn School of Medicine at Mount Sinai
NCT ID: NCT05419089
Sites in New Jersey: - Valley - Mount Sinai Comprehensive Cancer Care — Paramus, New Jersey
Phase 1 Recruiting Industry
This is a multicenter Phase 1b, open label, dose-escalation and cohort-expansion study, evaluating the safety, tolerability, pharmacokinetics (PK), preliminary antitumor activity, and effect of biomarkers of zanzalintinib administered alon…
Sponsor: Exelixis
NCT ID: NCT05176483
Sites in New Jersey: - Exelixis Clinical Site #88 — East Brunswick, New Jersey
- Exelixis Clinical Site #105 — Hackensack, New Jersey